medica glp-1 coverage Paving the way for expanded | Insights & Events GLP-1 Weight-Loss Drug Demonstration Begins

Despite GLP-1s being indicated for diabetes, obesity and some heart conditions, the Bridge program will almost solely be available to beneficiaries seeking weight management solutions

EClinicalMedicine 55

The limited duration and small sample size may have contributed to the lack of behavioral effects, and ongoing trials are exploring repeated dosing strategies (e.g., NCT06252623, NCT06691243)

The imbalance of gut microbiota will reduce the production of SCFAs, weaken the ability to activate SCFAs receptors, and affect GLP-1 secretion, resulting in abnormal glucose metabolism and lipid metabolism (Ma et al., 2019)

Are there specific cancer types I should be more concerned about with these medications

Neuroscience 180 , 111121